Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP EBITDA Margin

EBITDA as a percentage of revenue.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 5140.2 pp.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
3772.2%— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years+5140.2 pp——
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
3772.2%
Year-over-year change
—

EBITDA Margin vs competitors

How ORMP compares with its peers on the latest reported figures

  • ORMP's FY2025 EBITDA Margin of 3772.2% is the highest of the 9 companies compared; the peer median is -5103.2%.
  • Over three fiscal years its change of +5140.2 pp compares with a peer median of +32.0 pp.
ORMP Competitors Peer median
EBITDA Margin for ORMP and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253772.2% —+5140.2 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-265.8% +218.0 pp—
OVIDOvid Therapeutics Inc.LTM Mar 2026-337.0% +4411.9 pp+3368.5 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4623.1% -3172.4 pp+10652.3 pp
IMAImageneBio IncFY2025-5583.3% -4582.4 pp-5147.8 pp
CLNNClene Inc.LTM Mar 2026-21792.5% -14931.4 pp-5585.1 pp
CNTBConnect Biopharma Holdings LimitedFY2025-85279.7% -85223.0 pp—
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
KLRSKalaris Therapeutics IncFY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding ORMP) -5103.2%-3877.4 pp+32.0 pp

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.7M2.7M1.34M02M
Cost of Revenue000193K1.99M
Gross Profit2.7M2.7M1.34M(193K)13K
Gross Margin100.0%100.0%100.0%—0.7%
Research & Development20.99M27.64M8.97M6.32M6.38M
Selling, General & Admin5.94M15.66M8.14M6.46M8.72M
Operating Expenses26.93M43.3M17.11M12.78M15.1M
Depreciation & Amortization77K3.62M196K193K121K
EBITDA(25.04M)(36.98M)7.32M(14.87M)75.45M
EBITDA Margin-926.3%-1368.0%546.3%—3772.2%
Operating Income(24.22M)(40.6M)(15.77M)(12.78M)(15.09M)
Operating Margin-896.2%-1502.0%-1176.8%—-754.4%
Interest Income347K3.57M8.03M02.37M
Interest Expense6K03.58M853K0
Other Income / Expenses893K2.93M20.86M(3.14M)90.41M
Income Before Tax(22.99M)(37.66M)5.09M(15.92M)75.32M
Pre-Tax Margin-850.5%-1393.4%379.7%—3766.2%
Income Tax Expense(2.88M)100K03.18M11.31M
Net Income(22.24M)(37.76M)5.53M(19.1M)64.05M
Net Margin-822.7%-1397.1%412.3%—3202.5%
EPS (Basic)(0.78)(0.97)0.14(0.47)1.53
EPS (Diluted)(0.78)(0.97)0.14(0.47)1.50
Weighted Avg Shares28.47M39M40.32M40.83M41.4M
Weighted Avg Shares (Diluted)28.47M39M40.57M40.83M42.42M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.